Group
VEGF mAb
The data below refer to patients treated with VEGF mAb as the sole drug class,
excluding any concurrent use of drugs from other groups.
Combination therapy data are available in the section below.
Location
Treated site
Individual Drugs
Select a drug to view its individual evidence base (drug + SBRT, no other concurrent systemic drugs). Drugs without available data are shown greyed out.
Bevacizumab
Ramucirumab
No data